| Metric | Value (₹ Cr) | vs Q3 FY25 |
|---|---|---|
| Revenue | 3.1K | 4.7% |
| Total Income | 3.3K | 0.7% |
| Expenditure | 2.8K | 0.1% |
| PBT | 513.11 | 3.9% |
| Net Profit | 424.65 | 10.4% |
| OPM | 22.19% | 22.09pp |
| NPM | 12.75% | 1.23pp |
| EPS | 10.30 | 9.0% |
Mankind Pharma Reports 27% Revenue Growth in Q4FY25, Surpasses INR 10,000 Cr in Domestic Revenue for FY25
21 May 2025 · 21 May 2025, 06:13 pm
Summary
Mankind Pharma has announced its financial results for the fourth quarter and full year ended 31st March 2025. The company's revenue grew by 27% in Q4FY25 with adjusted EBITDA margins at ~23%. The domestic revenue surpassed INR 10,000 Cr in FY25. The company's performance was driven by continued outperformance in Chronic, strong growth in Consumer segment and BSV consolidation.
Key Highlights
- 1
Revenue from Operations at INR 3,079 Cr, up by 27% YoY
- 2
Domestic revenue at INR 2,544 Cr, up 18% YoY, Exports at INR 535 Cr, up 100% YoY
- 3
Adjusted EBITDA margin of 23.1% down by 120 bps YoY and PAT margin of 13.9%
- 4
Diluted EPS of INR 10.3 down by 12.5% YoY (FV Re.1)
- 5
Revenue from Operations at INR 12,207 Cr, up by 19% YoY
- 6
Domestic revenue at INR 10,675 Cr, up 13% YoY, Exports at INR 1,532 Cr, up 88% YoY
- 7
Adjusted EBITDA margin of 25.9% up by 130 bps YoY and PAT margin of 16.4%
- 8
Diluted EPS of INR 49.1, up by 3% YoY (FV Re.1)
- 9
Market share has increased from 4.4% in Mar-24 to 4.8% as of Mar-25 on account of BSV acquisition
- 10
Revenue growth of 100% YoY in Q4 FY25 in Exports
- 11
Mankind (excl. BSV) has launched 1 product in Q4 FY25 and 5 products in FY25 taking the total launched products to 44 in US
Management Comments
Mr. Rajeev Juneja — Vice Chairman & Managing Director
Mankind’s revenue grew by 27% with adjusted EBITDA margins at ~23% in Q4 FY25 led by continued 1.3x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. In FY25, reported revenue growth was 19% with adj. EBITDA margin of ~26% This has been a transformative year at Mankind with several strategic initiatives to ensure higher productivity and outperform IPM as seen in the past. BSV integration is progressing well with key focus on R&D, improving MR productivity & scaling mandate brands across domestic & International business. During FY25, we’ve laid a strong foundation to deliver long-term sustainable growth led by four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and high entry barrier super specialty portfolio of BSV.”
Informational and educational content only. Not investment advice.